Sana and Mayo Clinic will collaborate to develop and standardize end-to-end protocols for SC451, covering product handling, surgical procedures and post-treatment care. The partnership aims to enable consistent, scalable delivery across Mayo facilities and global sites, drawing on clinical operations, surgical refinement and biomarker-driven trial design.

SC451 is a gene-modified, stem cell–derived pancreatic islet cell therapy engineered with hypoimmune technology to evade immune detection and function without immunosuppression. Investigator-sponsored data show transplanted donor islets survive and produce insulin for over 14 months in a type 1 diabetes patient, supporting potential single-treatment efficacy.

Mayo Clinic has agreed to make an initial equity investment in Sana with an option for additional funding under the collaboration terms. This financial commitment reflects Mayo’s confidence in SC451’s potential and strengthens the strategic alignment between the organizations.

Sana plans to file an IND application and initiate a Phase 1 clinical trial of SC451 by year-end. Joint efforts will focus on finalizing trial protocols, refining surgical workflows and identifying biomarkers for patient selection and longitudinal monitoring.